Vertebral compression fractures (VCFs) can now be detected using Avicenna.AI’s CINA-VCF AI imaging tool, which has received 510(k) clearance from the US Food and Drug Administration (FDA). This AI imaging tool is designed for patients undergoing routine CT scans. This clearance marks a significant milestone for the company as it expands its portfolio of AI-powered medical imaging solutions.
The CINA-VCF imaging tool is specifically used for the detection of unsuspected vertebral compression fractures during chest or abdomen computed tomography (CT) scans. Avicenna.AI validated its algorithm using 474 CT scans performed on patients not specifically undergoing evaluations for pulmonary embolism and utilized 38 different scanner models to ensure robustness and accuracy.
This FDA clearance follows previous approvals for Avicenna.AI’s other devices. In March 2024, the FDA cleared CINA-iPE and CINA-ASPECTS, tools designed for detecting pulmonary embolism and assessing stroke severity, respectively. Additionally, Avicenna.AI has received FDA clearance for AI-powered CT scan tools that help detect intracranial hemorrhage, aortic dissection, and large vessel occlusion.
Highlighting Early Detection Benefits with New Imaging Tool for Vertebral Compression Fractures
Vertebral compression fractures occur when weakened vertebrae collapse, often due to osteoporosis, a condition that reduces bone density and strength. Avicenna.AI’s CEO Cyril Di Grandi emphasized the significance of early detection: “By detecting vertebral compression fractures early, we aim to help patients maintain better mobility and independence, enhance the well-being of those at risk, and reduce the burden on healthcare systems worldwide.”
Founded in 2018, the French medical imaging AI company has made significant strides in the healthcare AI sector. In February 2023, Avicenna.AI secured $10 million in a Series A funding round backed by Innovacom and CEMAG Invest. AI-assisted CT imaging represents a key area of innovation in healthcare, with global revenues projected to reach $18.8 billion by 2027, according to a report by GlobalData’s Medical Intelligence Center.
The healthcare AI space continues to attract significant interest and investment. Companies like Philips and Synthetic MR have recently collaborated to enhance the diagnosis of neurological disorders using advanced quantitative brain imaging tools. The Smart Quant Neuro 3D MRI machine software suite, for instance, employs AI to analyze brain tissues, including white matter, gray matter, cerebrospinal fluid, and myelin, thereby aiding radiologists and healthcare professionals in identifying abnormalities and suggesting potential treatment pathways based on patients’ medical histories.
AI Imaging Tool CINA-VCF Enhances Diagnostic Accuracy and Efficiency in Healthcare
Integrating AI systems and computer vision into medical imaging technology assists in streamlining the workloads of healthcare professionals and improving diagnostic accuracy. By automatically detecting anomalies in scan images, AI tools like CINA-VCF not only enhance the efficiency of radiologists but also play a crucial role in early diagnosis, which is vital for patient outcomes.
Avicenna.AI’s achievement in securing FDA clearance for CINA-VCF imaging tool underscores the growing importance of AI in medical imaging. As the company continues to innovate and expand its range of AI tools, it contributes to the broader goal of improving patient care and optimizing healthcare delivery systems. The detection of vertebral compression fractures, a common yet often undiagnosed condition, exemplifies the practical benefits of AI in identifying and managing medical conditions that can significantly impact patients’ quality of life.
In summary, the FDA clearance for Avicenna.AI’s CINA-VCF imaging tool represents a significant advancement in the use of AI for medical imaging. By enabling the early detection of vertebral compression fractures, this tool has the potential to improve patient mobility, independence, and overall well-being while alleviating the burden on healthcare systems. Avicenna.AI’s continued innovation in this field highlights the transformative potential of AI in healthcare, paving the way for more efficient, accurate, and accessible medical diagnostics.
Resource: Avicenna.AI, June 12, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
